Stock Price Quote

GLENMARK PHARMACEUTICALS LTD.

NSE : GLENMARKBSE : 532296ISIN CODE : INE935A01035Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE1905.1587.2 (+4.8 %)
PREV CLOSE ( ) 1817.95
OPEN PRICE ( ) 1817.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 96575
TODAY'S LOW / HIGH ( )1816.45 1919.00
52 WK LOW / HIGH ( )1274.7 1879.2
NSE1904.0085.2 (+4.68 %)
PREV CLOSE( ) 1818.80
OPEN PRICE ( ) 1821.90
BID PRICE (QTY) 1904.00 (47078)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3420276
TODAY'S LOW / HIGH( ) 1813.10 1920.00
52 WK LOW / HIGH ( )1275.5 1879.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 18-11 1977
Management Info
Glenn Saldanha - Chairman Glenn Saldanha - Managing Director
Registered Office

Address B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, ,
Mumbai,
Maharashtra-400026

Phone

Email complianceofficer@glenmarkpharma.com

Website www.glenmarkpharma.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE

NEWS

01Jul Glenmark Pharmaceuticals informs about
Pursuant to Regulation 30 (5) of the SEBI (Listing Obligations and Discl..
24Jun Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that it attached media release tit..
24Jun Glenmark Pharmaceuticals launches TEVI
Glenmark Pharmaceuticals has launched TEVIMBRA (tislelizumab) in India f..
24Jun Glenmark Pharmaceuticals rises on laun
Glenmark Pharmaceuticals is currently trading at Rs. 1695.00, up by 8.90..
19Jun Glenmark Pharmaceuticals informs about
Glenmark Pharmaceuticals has informed that the exchange has received the..

Financials

in Millions
QTR Mar 25 ANNUAL 25
Net Profit1477.616103.5
Gross Profit 1811.55 21540.18
Operating Profit 4289.7726005.46
Net Sales 20094.9392264.09

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  34611.10 (0.76%)
M.Cap ( in Cr)73546.17
NGL Fine-Chem (BSE)
peergroup  1325.00 (4.33%)
M.Cap ( in Cr)818.59
Emcure Pharma (BSE)
peergroup  1283.55 (2.18%)
M.Cap ( in Cr)24324.34
Kwality Pharma (BSE)
peergroup  1167.55 (2.08%)
M.Cap ( in Cr)1211.47
Shilpa Medicare (BSE)
peergroup  870.70 (2.76%)
M.Cap ( in Cr)8514.65

Shareholding Pattern

PROMOTERS 46.65%
NON-INSTITUTION 15.56%
MUTUAL FUNDS/UTI 12.86%
FI/BANKS/INSURANCE 0.43%
GOVERNMENT 0.04%
FII 0%

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. was incorporated in the year 1977. Its today's share price is 1905.15. Its current market capitalisation stands at Rs 53763.49 Cr. In the latest quarter, company has reported Gross Sales of Rs. 93936.65 Cr and Total Income of Rs.90591.43 Cr. The company's management includes Pradeep Kumar Sinha, Dipankar Bhattacharjee, Vijayalakshmi Iyer, Saira Ramasastry, B E Saldanha, Cherylann Pinto, Glenn Saldanha, Glenn Saldanha, Harish Kuber.

It is listed on the BSE with a BSE Code of 532296 , NSE with an NSE Symbol of GLENMARK and ISIN of INE935A01035. It's Registered office is at B/2 Mahalaxmi Chambers,22 Bhulabhai Desai Road, Mumbai-400026, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Arthur Andersen & Associates, Price Waterhouse, Suresh Surana & Associates LLP, VK Bahri & Co, Walker Chandiok & Co LLP, Walker, Chandiok & Co, Walker, Chandiok & Co LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.